Month: September 2020

Palatin Technologies, Inc. Announces Fourth Quarter and Fiscal Year 2020 Financial Results and Provides a Business Update

– $82.9 Million in Cash and Cash Equivalents at June 30, 2020 – Mutual Termination of License Agreement with AMAG Pharmaceuticals for Vyleesi® in July 2020 Resulted in Palatin Receiving $12 Million from AMAG Plus $4.3 Million Due March 31, 2021 – Phase 2 Study Data of PL9643 for the Treatment of Dry Eye Disease …

Palatin Technologies, Inc. Announces Fourth Quarter and Fiscal Year 2020 Financial Results and Provides a Business Update Read More »

Palatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year End 2020 Results; Teleconference and Webcast to be held on September 28, 2020

Sep 24, 2020, 16:00 ET CRANBURY, N.J., Sept. 24, 2020 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) will announce its fourth quarter and fiscal year end 2020 operating results on Monday, September 28, 2020 before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by …

Palatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year End 2020 Results; Teleconference and Webcast to be held on September 28, 2020 Read More »

Palatin Technologies To Present At The H.C. Wainwright & Co. 22nd Annual Global Investment Conference

Sep 10, 2020, 17:47 ET CRANBURY, N.J., Sept. 10, 2020 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, announced today that it will be presenting at the H.C. Wainwright & Co., 22nd Annual …

Palatin Technologies To Present At The H.C. Wainwright & Co. 22nd Annual Global Investment Conference Read More »

Scroll to Top